Cognite Atlas AI™ Drives Customer Momentum with New Major Release, Accelerates Adoption of Agentic AI to Unlock More Industrial Value
9.9.2025 22:00:00 EEST | Business Wire | Press release
Cognite, the global leader in industrial AI, today announced a major release of Cognite Atlas AI™, the only low-code industrial AI agent workbench to power agents with real-time, AI-ready operational technology (OT), information technology (IT), and engineering data. This rapid momentum includes onboarding new customers weekly, a testament to its effectiveness in driving industrial digital transformation and value. The latest product release will be showcased at an oversubscribed Atlas AI Summit with hundreds of attendees in Tokyo, Japan, on September 10th.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909488860/en/
Cognite, the global leader in industrial AI, today announced a major release of Cognite Atlas AI™, the only low-code industrial AI agent workbench to power agents with real-time, AI-ready operational technology (OT), information technology (IT), and engineering data.
“This latest release of Cognite Atlas AI is a true game-changer,” said Nobuyoshi Hojo, General Manager, Technology & Engineering Center, at Idemitsu Kosan Co., Ltd. “AI agents are amplifying our impact and improving safety, reducing plant downtime, and unlocking new levels of innovation across our refineries. We are not merely automating tasks; we are leveraging reliable AI-driven insights to continuously improve our business processes and generate significant value across the organization. This is a crucial step in our digital transformation journey.”
A recent survey from PwC reveals a significant gap between AI exploration and full-scale adoption, with 79% of businesses experimenting with AI agents, yet only 19% deploying them at scale. To help bridge this divide, this latest milestone release is designed to accelerate and simplify the deployment of production-ready AI agents. This new release includes powerful features that empower organizations to implement AI solutions faster and with greater confidence. Key enhancements include:
- Seamless Integration: Automate time-consuming tasks by integrating agents directly with existing Cognite applications to perform root cause analysis, troubleshoot processes, create work packages, analyze performance, and more.
- Streamlined Agent Creation: Build agents 10x faster with preconfigured templates for analyzing time series data, generating work packages, gathering cross-data source information, summarizing shift handovers, and classifying work orders.
- Purpose-Built Industrial Tools: Accelerate scaling by quickly deploying agents to query the industrial knowledge graph and find relevant information.
- Secure & Governed Operations: Ensure reliability and trust through secure and well-governed agent operations with granular user access controls.
"Cognite’s latest release for Cognite Atlas AI is a leap toward narrowing the pilot‑to‑production gap," said Joe Lamming, Senior Analyst, Technical Lead, AI Applied, at Verdantix. "Our research shows scalable agents depend on extremely precise context engineering – domain models that faithfully represent what matters, machine‑traversable semantic connections, massive concurrency, governed tool access, and drill‑down observability – well beyond what a chat interface alone provides. Atlas AI natively extends Cognite's DataOps platform to automate common operational tasks in a user-configurable, domain-specific low-code workbench. We see such product suites as there to enable scoped, production‑grade automations with human oversight – not just early-adopter demos – for more organizations."
"The industrial world is at a crucial inflection point where the true value of AI lies not in isolated experiments, but in scalable, production-ready solutions," said Chirayu Shah, Chief Product Officer, Cognite. "Our latest release of Cognite Atlas AI is a direct response to this need. We're empowering our customers to accelerate their digital transformation and unlock significant value by turning AI agents into a foundational part of their operations. We have customers across industry verticals in production with Atlas AI, in the Americas, EMEA, and Japan."
Register to attend Cognite's global Industrial AI and Data Conference, Impact 2025, to hear more from industry leaders about Atlas AI and how agentic AI is transforming operations.
About Cognite
Cognite makes GenAI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.com and follow us on LinkedIn and X.
About Cognite Atlas AI™
Cognite Atlas AI™ unlocks the full potential of industrial data, empowering teams to make faster, more confident decisions and accelerate operational efficiency and innovation at scale. Cognite Atlas AI includes a growing library of preconfigured agents, a low-code agent builder, purpose-built industrial tools, and a curated selection of LLMs with benchmarking. It also utilizes the real-time OT, IT, and engineering data in Cognite Data Fusion®, ensuring that agents deliver accurate, traceable, and trustworthy results for industrial workflows.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909488860/en/
Contacts
Media Contact:
Michelle Holford
Vice President, Global PR
Michelle.Holford@Cognite.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom